Terms: = Brain cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
317 results:
1. RAPID resistance to BET inhibitors is mediated by fgfr1 in glioblastoma.
Jermakowicz AM; Kurimchak AM; Johnson KJ; Bourgain-Guglielmetti F; Kaeppeli S; Affer M; Pradhyumnan H; Suter RK; Walters W; Cepero M; Duncan JS; Ayad NG
Sci Rep; 2024 Apr; 14(1):9284. PubMed ID: 38654040
[TBL] [Abstract] [Full Text] [Related]
2. B7-H3 Expression in Breast cancer and brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
3. LymphoDose: a lymphocyte dose estimation framework-application to brain radiotherapy.
de Kermenguy F; Benzazon N; Maury P; Vauclin R; M'hamdi M; Cifliku V; Limkin E; Diallo I; Morel D; Milewski C; Clémenson C; Mondini M; Deutsch E; Robert C
Phys Med Biol; 2024 Apr; 69(10):. PubMed ID: 38593817
[No Abstract] [Full Text] [Related]
4. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract] [Full Text] [Related]
5. Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.
Tazhibi M; McQuillan N; Wei HJ; Gallitto M; Bendau E; Webster Carrion A; Berg X; Kokossis D; Zhang X; Zhang Z; Jan CI; Mintz A; Gartrell RD; Syed HR; Fonseca A; Pavisic J; Szalontay L; Konofagou EE; Zacharoulis S; Wu CC
J Transl Med; 2024 Mar; 22(1):320. PubMed ID: 38555449
[TBL] [Abstract] [Full Text] [Related]
6. Bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
8. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
9. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C; MacDonald T; Mueller S; Faison SL; Allen JE; Naderer OJ; Ramage SC; Tarapore RS; McGovern SL; Khatua S; Zaky W; Gardner SL
Neuro Oncol; 2024 May; 26(Supplement_2):S155-S164. PubMed ID: 38400780
[TBL] [Abstract] [Full Text] [Related]
10. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract] [Full Text] [Related]
11. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract] [Full Text] [Related]
12. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
[TBL] [Abstract] [Full Text] [Related]
13. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
14. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
15. Cortical myelin and thickness mapping provide insights into whole-brain tumor burden in diffuse midline glioma.
Zhang S; Yang X; Tan Q; Sun H; Chen D; Chen Y; Zhang H; Yang Y; Gong Q; Yue Q
Cereb Cortex; 2024 Jan; 34(1):. PubMed ID: 38112602
[TBL] [Abstract] [Full Text] [Related]
16. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract] [Full Text] [Related]
17. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemistry Detection of Histone H3 K27M Mutation in Human Glioma Tissue.
Tarapore RS; Arain S; Blaine E; Hsiung A; Melemed AS; Allen JE
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):96-101. PubMed ID: 38073235
[TBL] [Abstract] [Full Text] [Related]
19. The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells.
Reisbeck L; Linder B; Tascher G; Bozkurt S; Weber KJ; Herold-Mende C; van Wijk SJL; Marschalek R; Schaefer L; Münch C; Kögel D
Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1451-C1469. PubMed ID: 37899749
[TBL] [Abstract] [Full Text] [Related]
20. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract] [Full Text] [Related]
[Next]
